Parabase Genomics’ is committed to improving neonatal care through the development of early diagnostics for actionable inherited disorders. The company’s NewbornDx Tests™ are designed to be rapid and less invasive, using dried blood spots, and incorporate the most damaging disorders. Physicians can now make precise treatment decisions based on an individual’s molecular profile rather than severe symptomology. NewbornDx will assist neonatologists to make prompt and informed decisions while the patient is still in the hospital by matching them to the best treatment and clinical trial options.
The company’s advisors are world leaders in newborn medicine, genomic technologies and informatics.